Market Summary
USD375.40-0.20
Market Closed-0.05%
WST Alerts
WST Stock Price
WST RSI Chart
WST Valuation
WST Price/Sales (Trailing)
WST Profitability
WST Fundamentals
WST Revenue
WST Earnings
Price Action
52 Week Range
206.19415.73
(Low)(High)
Last 7 days
-4.8%
Last 30 days
-4.6%
Last 90 days
1.7%
Trailing 12 Months
47.7%
WST Financial Health
WST Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for WST
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-30 | Favorite Annette F | acquired | 166,940 | 83.47 | 2,000 | sr. vp & chief hr officer |
2023-08-30 | Favorite Annette F | sold | -829,277 | 414 | -2,000 | sr. vp & chief hr officer |
2023-08-22 | Reiss-Clark Cindy | acquired | 915,007 | 263 | 3,477 | chief commercial officer |
2023-08-22 | Reiss-Clark Cindy | sold | -1,367,640 | 393 | -3,477 | chief commercial officer |
2023-08-11 | Lai Quintin J | sold | -8,337,490 | 395 | -21,101 | vp strat & investor relations |
2023-08-11 | Lai Quintin J | acquired | 2,646,110 | 125 | 21,101 | vp strat & investor relations |
2023-08-09 | Witherspoon Charles | acquired | 231,613 | 137 | 1,680 | vp & treasurer |
2023-08-09 | Witherspoon Charles | sold | -666,187 | 396 | -1,680 | vp & treasurer |
2023-08-08 | Green Eric Mark | sold | -17,369,800 | 394 | -44,000 | president & ceo |
2023-08-08 | Abraham Silji | acquired | 836,482 | 102 | 8,160 | svp, chief technology officer |
Which funds bought or sold WST recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 2,429,790 | 2,429,790 | 0.02% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 217 | 2,301 | -% |
2023-09-20 | BARCLAYS PLC | added | 84.93 | 25,507,000 | 50,000,000 | 0.03% |
2023-09-12 | Farther Finance Advisors, LLC | added | 28.25 | 25,501 | 86,829 | 0.02% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 756 | 8,032 | -% |
2023-09-05 | Covenant Partners, LLC | unchanged | - | 31,788 | 337,721 | 0.12% |
2023-09-01 | Portside Wealth Group, LLC | new | - | 1,031,520 | 1,031,520 | 0.19% |
2023-08-30 | Western Wealth Management, LLC | unchanged | - | 49,972 | 530,883 | 0.04% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | 227 | 15,239 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | 671,688 | 7,136,120 | 0.07% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
WST Alerts
Schedule 13G FIlings of West Pharmaceutical Services
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 3.1% | 2,301,161 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 12.14% | 8,988,409 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 11.0% | 8,148,624 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 8.4% | 6,241,901 | SC 13G/A | |
| Feb 04, 2022 | franklin resources inc | 3.8% | 2,848,869 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 10.9% | 8,094,288 | SC 13G/A | |
| Jan 25, 2022 | blackrock inc. | 10.9% | 8,094,288 | SC 13G/A | |
| Apr 12, 2021 | blackrock inc. | 10.1% | 7,467,809 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 6.2% | 4,624,247 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 11.21% | 8,289,370 | SC 13G/A |
Recent SEC filings of West Pharmaceutical Services
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 21, 2023 | 8-K/A | Current Report | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 27, 2023 | 8-K | Current Report |
Peers (Alternatives to West Pharmaceutical Services)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 182.5B | 30.4B | -1.37% | -4.99% | 28.7 | 6.01 | -1.49% | 0.14% |
ABT | 167.5B | 40.2B | -6.47% | -2.73% | 32.45 | 4.16 | -11.68% | -39.67% |
MDT | 105.0B | 31.6B | -2.70% | -3.25% | 28.96 | 3.33 | 1.57% | -30.40% |
IDXX | 35.9B | 3.5B | -11.25% | 30.83% | 45.38 | 10.22 | 6.21% | 19.20% |
WST | 27.7B | 2.9B | -4.60% | 47.73% | 53.48 | 9.68 | -2.14% | -24.34% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -1.70% | 33.64% | 325.17 | 10.1 | 16.30% | 250.21% |
LNTH | 4.5B | 1.1B | -2.64% | -5.47% | 135.07 | 4.01 | 69.36% | 3.03% |
NEOG | 4.2B | 822.4M | -14.46% | 31.58% | -184 | 5.12 | 56.01% | -147.34% |
QDEL | - | - | -7.20% | -1.41% | - | - | - | - |
| SMALL-CAP | ||||||||
VIVO | 1.5B | 301.6M | 2.29% | 56.91% | -550.1 | 4.93 | -3.75% | -104.51% |
HSKA | 1.2B | 254.9M | 2.45% | 31.18% | -62.25 | 4.89 | -1.22% | 15.74% |
CYRX | 653.5M | 240.7M | -3.82% | -45.97% | -15.31 | 2.72 | 4.82% | 85.44% |
AWH | 45.4M | 9.0M | 48.55% | -15.88% | -2.52 | 5.03 | 20.81% | 50.13% |
QTNT | 766.7K | 37.4M | -50.00% | -99.61% | -0.01 | 0.02 | -2.49% | 10.49% |
West Pharmaceutical Services News
Returns for WST
Cumulative Returns on WST
25.4%
10-Year Cumulative Returns
27.1%
7-Year Cumulative Returns
25.5%
5-Year Cumulative Returns
11.8%
3-Year Cumulative Returns
Risks for WST
What is the probability of a big loss on WST?
66.9%
Probability that West Pharmaceutical Services stock will be more than 20% underwater in next one year
27.3%
Probability that West Pharmaceutical Services stock will be more than 30% underwater in next one year.
11.5%
Probability that West Pharmaceutical Services stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does WST drawdown profile look like?
Y-axis is the maximum loss one would have experienced if West Pharmaceutical Services was unfortunately bought at previous high price.
Drawdowns
Financials for West Pharmaceutical Services
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.6% | 2,866 | 2,884 | 2,887 | 2,909 | 2,929 | 2,881 | 2,832 | 2,681 | 2,523 | 2,326 | 2,147 | 2,037 | 1,945 | 1,888 | 1,840 | 1,792 | 1,767 | 1,745 | 1,717 | 1,711 | 1,677 |
| Gross Profit | -2.7% | 1,093 | 1,123 | 1,136 | 1,175 | 1,195 | 1,189 | 1,176 | 1,086 | 993 | 873 | 768 | 710 | 663 | 626 | 606 | 586 | 574 | 558 | 545 | 541 | 530 |
| S&GA Expenses | 2.2% | 326 | 320 | 317 | 329 | 355 | 366 | 363 | 341 | 325 | 310 | 302 | 295 | 283 | 276 | 273 | 263 | 264 | 263 | 263 | 263 | 261 |
| R&D Expenses | 3.4% | 63.00 | 61.00 | 59.00 | 56.00 | 56.00 | 55.00 | 53.00 | 52.00 | 51.00 | 48.00 | 47.00 | 44.00 | 41.00 | 40.00 | 39.00 | 39.00 | 39.00 | 41.00 | 40.00 | 40.00 | 39.00 |
| EBITDA | -100.0% | - | 777 | 805 | 861 | 906 | 893 | 879 | 806 | 721 | 607 | 519 | 475 | 442 | 420 | 404 | 393 | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.27* | 0.28* | 0.30* | 0.31* | 0.31* | 0.31* | 0.30* | 0.29* | 0.26* | 0.24* | 0.23* | 0.23* | 0.22* | 0.22* | 0.22* | - | - | - | - | - |
| Interest Expenses | 11.4% | 9.00 | 8.00 | 8.00 | 9.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 |
| Earnings Before Taxes | -6.5% | 608 | 650 | 680 | 733 | 778 | 762 | 749 | 682 | 599 | 490 | 401 | 364 | 331 | 308 | 292 | 280 | 276 | 257 | 241 | 234 | 236 |
| EBT Margin | -100.0% | - | 0.23* | 0.24* | 0.25* | 0.27* | 0.26* | 0.26* | 0.25* | 0.24* | 0.21* | 0.19* | 0.18* | 0.17* | 0.16* | 0.16* | 0.16* | - | - | - | - | - |
| Net Income | -6.0% | 519 | 552 | 586 | 631 | 686 | 684 | 662 | 613 | 519 | 423 | 346 | 312 | 286 | 261 | 242 | 230 | 229 | 219 | 207 | 155 | 151 |
| Net Income Margin | -100.0% | - | 0.19* | 0.20* | 0.22* | 0.23* | 0.24* | 0.23* | 0.23* | 0.21* | 0.18* | 0.16* | 0.15* | 0.15* | 0.14* | 0.13* | 0.13* | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 410 | 439 | 388 | 402 | 382 | 331 | 337 | 284 | 307 | 298 | 276 | 281 | 247 | 241 | 215 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -1.5% | 3,670 | 3,724 | 3,617 | 3,317 | 3,362 | 3,295 | 3,314 | 3,143 | 2,934 | 2,740 | 2,794 | 2,583 | 2,392 | 2,247 | 2,341 | 2,174 | 2,123 | 2,036 | 1,979 | 1,946 | 1,874 |
| Current Assets | -3.3% | 1,874 | 1,937 | 1,920 | 1,734 | 1,771 | 1,691 | 1,742 | 1,598 | 1,477 | 1,327 | 1,374 | 1,238 | 1,111 | 978 | 1,059 | 1,004 | 944 | 868 | 894 | 850 | 767 |
| Cash Equivalents | -10.2% | 796 | 886 | 894 | 729 | 719 | 668 | 763 | 688 | 576 | 484 | 616 | 519 | 446 | 335 | 439 | 396 | 327 | 266 | 337 | 297 | 226 |
| Inventory | 0.5% | 449 | 447 | 415 | 413 | 412 | 417 | 378 | 354 | 345 | 310 | 321 | 295 | 275 | 251 | 236 | 230 | 232 | 226 | 215 | 207 | 208 |
| Net PPE | 3.8% | 1,261 | 1,215 | 1,158 | 1,069 | 1,077 | 1,066 | 1,058 | 1,007 | 973 | 931 | 943 | 883 | 840 | 828 | 839 | 812 | 823 | 815 | 822 | 822 | 827 |
| Goodwill | 0.2% | 108 | 108 | 107 | 104 | 107 | 109 | 110 | 109 | 110 | 110 | 111 | 109 | 108 | 107 | 108 | 107 | 108 | 105 | 106 | 106 | 107 |
| Liabilities | -2.6% | 923 | 947 | 932 | 846 | 937 | 969 | 978 | 940 | 901 | 911 | 939 | 864 | 786 | 756 | 768 | 686 | 678 | 667 | 583 | 594 | 592 |
| Current Liabilities | -4.4% | 512 | 535 | 519 | 457 | 565 | 585 | 594 | 559 | 473 | 483 | 503 | 448 | 375 | 344 | 342 | 335 | 313 | 301 | 284 | 289 | 288 |
| LT Debt, Non Current | -0.2% | 206 | 206 | 207 | 207 | 208 | 208 | 209 | 210 | 252 | 252 | 253 | 253 | 254 | 254 | 255 | 195 | 196 | 196 | 196 | 196 | 196 |
| Shareholder's Equity | -1.1% | 2,747 | 2,776 | 2,685 | 2,471 | 2,424 | 2,326 | 2,335 | 2,202 | 2,033 | 1,829 | 1,855 | 1,719 | 1,606 | 1,490 | 1,573 | 1,488 | 1,445 | 1,370 | 1,396 | 1,352 | 1,282 |
| Retained Earnings | 4.5% | 3,255 | 3,114 | 2,988 | 2,913 | 2,793 | 2,617 | 2,457 | 2,336 | 2,160 | 1,985 | 1,847 | 1,773 | 1,703 | 1,612 | 1,549 | 1,497 | 1,453 | 1,398 | 1,353 | 1,313 | 1,258 |
| Additional Paid-In Capital | -12.8% | 158 | 181 | 232 | 231 | 225 | 220 | 249 | 251 | 248 | 247 | 267 | 268 | 263 | 268 | 273 | 269 | 273 | 279 | 282 | 283 | 305 |
| Accumulated Depreciation | 1.4% | 1,282 | 1,264 | 1,228 | 1,164 | 1,169 | 1,171 | 1,158 | 1,140 | 1,125 | 1,098 | 1,092 | 1,056 | 1,018 | 989 | 981 | 968 | 964 | 945 | 931 | 924 | 910 |
| Shares Outstanding | -0.4% | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 | 74.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -0.5% | 707 | 711 | 724 | 654 | 675 | 647 | 584 | 572 | 500 | 504 | 473 | 430 | 420 | 377 | 367 | 334 | 314 | 291 | 289 | 297 | 284 |
| Share Based Compensation | 7.5% | 29.00 | 27.00 | 24.00 | 27.00 | 32.00 | 37.00 | 38.00 | 34.00 | 33.00 | 35.00 | 34.00 | 33.00 | 29.00 | 24.00 | 24.00 | 19.00 | 19.00 | 18.00 | 15.00 | 17.00 | 17.00 |
| Cashflow From Investing | -5.3% | -318 | -302 | -288 | -270 | -277 | -266 | -253 | -233 | -217 | -202 | -179 | -242 | -225 | -231 | -228 | -136 | -130 | -100 | -100 | -101 | -109 |
| Cashflow From Financing | -73.3% | -332 | -191 | -293 | -290 | -220 | -184 | -168 | -170 | -172 | -173 | -137 | -77.40 | -70.60 | -66.60 | -36.80 | -96.00 | -85.50 | -114 | -80.70 | -159 | -172 |
| Dividend Payments | 1.8% | 56.00 | 55.00 | 54.00 | 53.00 | 52.00 | 52.00 | 51.00 | 50.00 | 50.00 | 49.00 | 48.00 | 47.00 | 47.00 | 46.00 | 45.00 | 44.00 | 44.00 | 43.00 | 42.00 | 41.00 | 41.00 |
| Buy Backs | 125.0% | 261 | 116 | 203 | 203 | 176 | 147 | 137 | 137 | 137 | 137 | 116 | 116 | 116 | 116 | 83.00 | 83.00 | 83.00 | 106 | 71.00 | 118 | 118 |
WST Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 753.8 | $ 771.3 | $ 1,470.4 | $ 1,491.3 |
| Cost of goods and services sold | 462.4 | 449.8 | 907.7 | 885.2 |
| Gross profit | 291.4 | 321.5 | 562.7 | 606.1 |
| Research and development | 16.5 | 14.4 | 33.6 | 29.0 |
| Selling, general and administrative expenses | 88.4 | 81.5 | 174.4 | 164.9 |
| Other expense (income) (Note 15) | 4.0 | (2.8) | 16.9 | (5.9) |
| Operating profit | 182.5 | 228.4 | 337.8 | 418.1 |
| Interest expense, net | 2.7 | 1.8 | 4.9 | 4.0 |
| Interest income | (5.0) | (0.4) | (9.8) | (0.7) |
| Other nonoperating (income) expense | (0.1) | (0.2) | (0.1) | (0.2) |
| Income before income taxes and equity in net income of affiliated companies | 184.9 | 227.2 | 342.8 | 415.0 |
| Income tax expense | 34.8 | 44.2 | 58.4 | 65.4 |
| Equity in net income of affiliated companies | (5.0) | (5.5) | (10.7) | (12.7) |
| Net income | $ 155.1 | $ 188.5 | $ 295.1 | $ 362.3 |
| Net income per share: | ||||
| Basic (in dollars per share) | $ 2.08 | $ 2.53 | $ 3.96 | $ 4.87 |
| Diluted (in dollars per share) | $ 2.06 | $ 2.48 | $ 3.91 | $ 4.77 |
| Weighted average shares outstanding: | ||||
| Basic (in shares) | 74.3 | 74.4 | 74.4 | 74.4 |
| Diluted (in shares) | 75.4 | 75.8 | 75.5 | 75.9 |
WST Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 796.3 | $ 894.3 |
| Accounts receivable, net | 534.4 | 507.4 |
| Inventories | 449.4 | 414.8 |
| Other current assets | 94.1 | 103.0 |
| Total current assets | 1,874.2 | 1,919.5 |
| Property, plant and equipment | 2,543.3 | 2,386.6 |
| Less: accumulated depreciation and amortization | 1,282.0 | 1,228.3 |
| Property, plant and equipment, net | 1,261.3 | 1,158.3 |
| Operating lease right-of-use assets | 99.2 | 104.4 |
| Investments in affiliated companies | 202.8 | 204.9 |
| Goodwill | 108.0 | 107.3 |
| Intangible assets, net | 16.8 | 18.4 |
| Deferred income taxes | 67.0 | 65.6 |
| Other noncurrent assets | 40.3 | 38.4 |
| Total Assets | 3,669.6 | 3,616.8 |
| Current liabilities: | ||
| Notes payable and other current debt | 2.2 | 2.2 |
| Accounts payable | 218.0 | 215.4 |
| Accrued salaries, wages and benefits | 85.4 | 76.8 |
| Income taxes payable | 26.7 | 24.8 |
| Operating lease liabilities | 16.2 | 16.0 |
| Other current liabilities | 163.1 | 183.8 |
| Total current liabilities | 511.6 | 519.0 |
| Long-term debt | 205.6 | 206.7 |
| Deferred income taxes | 15.4 | 14.3 |
| Pension and other postretirement benefits | 27.3 | 28.2 |
| Operating lease liabilities | 87.3 | 93.0 |
| Deferred compensation benefits | 20.6 | 19.1 |
| Other long-term liabilities | 55.1 | 51.6 |
| Total Liabilities | 922.9 | 931.9 |
| Commitments and contingencies | ||
| Equity: | ||
| Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding | 0.0 | 0.0 |
| Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 73.9 million and 74.1 million | 18.8 | 18.8 |
| Capital in excess of par value | 158.2 | 232.2 |
| Retained earnings | 3,254.6 | 2,987.8 |
| Accumulated other comprehensive loss | (183.5) | (183.0) |
| Treasury stock, at cost (1.4 million and 1.2 million shares) | (501.4) | (370.9) |
| Total Equity | 2,746.7 | 2,684.9 |
| Total Liabilities and Equity | $ 3,669.6 | $ 3,616.8 |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.